All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, August 16, 2022

Collaboration

Home » Topics » Deals and M&A » Collaboration
  • Woman and 3d brain
    April 26, 2022
    By Doris Yu

    Genequantum collaborates with Aimed Bio to develop ADC for brain tumors

    Genequantum Healthcare Co. Ltd. will work with Aimed Bio Inc. to co-develop an antibody-drug conjugate (ADC) to treat brain and other cancers, working toward an IND filing in 2023. Aimed Bio will focus on antibody development, while Genequantum will work on linker-payload development. “Since we have a plan to market and sell the product globally, we will conduct a phase I clinical trial in the U.S., Australia, South Korea, and China as a priority,” Do-Hyun Nam, founder, chairman, and chief technology officer of Aimed, told BioWorld.
  • April 20, 2022
    By Doris Yu

    Genequantum collaborates with Aimed Bio to develop ADC for brain tumors

    Genequantum Healthcare Co. Ltd. will work with Aimed Bio Inc. to co-develop an antibody-drug conjugate (ADC) to treat brain and other cancers, working toward an IND filing in 2023.
  • Dolores schendel medigene
    Feb. 22, 2022
    By Richard Staines

    Biontech and Medigene join forces to research TCR-based immunotherapies

    Biontech SE and Medigene AG have signed a three-year research collaboration to develop T-cell receptor (TCR) based immunotherapies against cancer. Medigene will receive €26 million ($29.5 million) up front and could receive hundreds of millions of euros per drug in milestone payments from the deal, which will also covers research funding for the period of the collaboration.
Read More

Authors

  • Nuala Moran
  • Lee Landenberger
  • Michael Fitzhugh
  • Randy Osborne
  • Jihyun Kim
  • Cormac Sheridan
More Authors

Pages

  • Med-tech collaborations in 2021
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing